

Supporting Information


Synthesis of Isoxazolidine-containing Uridine Derivatives as Caprazamycin Analogues

Mayumi Yamaguchi,¹ Akira Matsuda,¹ and Satoshi Ichikawa^{1,2,*}

¹Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku,
Sapporo 060-0812, Japan, ²Center for Research and Education on Drug Discovery,
Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan


List of contents



NMR spectra of newly synthesized compounds	Page	S2-49
---	-------------	--------------





11

(500 MHz, CDCl₃)














(125 MHz, CDCl₃)














(125 MHz, CDCl₃)









21a


(125 MHz, CDCl₃)






17


(500 MHz, CDCl₃)






17


(100 MHz, CDCl₃)







18


(500 MHz, CDCl₃)



X : parts per Million : 1H









19


(125 MHz, CDCl₃)






14b


(500 MHz, CDCl₃)







14b


(125 MHz, CDCl₃)










X : parts per Million : ^{13}C












21b

(100 MHz, CDCl₃)




X : parts per Million : 13C







24 from 21a

(500 MHz, CD₃OD)









24 from 21b


(125 MHz, CD₃OD)






26

(500 MHz, CDCl_3)





X : parts per Million : 1H



26


(125 MHz, CDCl₃)






27

(500 MHz, CDCl₃)




X : parts per Million : 1H






27


(125 MHz, CDCl₃)




X : parts per Million : 13C

**28a**(500 MHz, CD₃OD)










28b

(125 MHz, CDCl₃)




X : parts per Million : 13C







30a

(125 MHz, DMSO- d_6)




X : parts per Million : ^{13}C







30b


(125 MHz, CD₃OD)






29a
(500 MHz, CDCl₃)






29a


(125 MHz, CDCl₃)




X : parts per Million : 13C




29b
(500 MHz, CDCl₃)




X : parts per Million : 1H




X : parts per Million : 1H





(125 MHz, DMSO-*d*₆)



X : parts per Million : 13C

